{"nctId":"NCT03126227","briefTitle":"Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES)","startDateStruct":{"date":"2017-05-08","type":"ACTUAL"},"conditions":["Peanut Allergy"],"count":506,"armGroups":[{"label":"AR101 Powder Provided in Capsules","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: AR101"]},{"label":"Placebo powder","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo"]}],"interventions":[{"name":"AR101","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Ages 4 to 17 years, inclusive\n* History of physician-diagnosed peanut allergy that includes allergic signs and symptoms within two hours of known oral exposure to peanut\n* Mean peanut wheal diameter on SPT of at least 8mm and elevated psIgE of at least 14 kUA/L at screening\n* Written informed consent from the subject's parent/guardian\n* Written assent from the subject as appropriate (per local regulatory requirements)\n* Use of effective birth control by sexually active female subjects of childbearing potential\n\nKey Exclusion Criteria:\n\n* Subjects in whom the clinical diagnosis of peanut allergy is uncertain\n* Severe or uncontrolled asthma\n* History of cardiovascular disease, including uncontrolled or inadequately controlled hypertension\n* History of severe or life-threatening episode of anaphylaxis or anaphylactic shock within 60 days of screening\n* History of eosinophilic esophagitis (EoE), other eosinophilic gastrointestinal disease, chronic, recurrent, or severe gastroesophageal reflux disease (GERD), symptoms of dysphagia or recurrent gastrointestinal symptoms of undiagnosed etiology\n* History of a mast cell disorder, including mastocytosis, urticaria pigmentosa, chronic idiopathic or chronic physical urticaria beyond simple dermatographism (e.g., cold urticaria, cholinergic urticaria), and hereditary or idiopathic angioedema\n* Any other condition that, in the opinion of the Investigator, precludes participation for reasons of safety","healthyVolunteers":false,"sex":"ALL","minimumAge":"4 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Frequency of Treatment Emergent Adverse Events, Including Serious Adverse Events","description":"Frequency of Treatment Emergent Adverse Events, including Serious Adverse Events, during the overall study period.\n\nTreatment-emergent adverse events were defined as adverse events with onset after the first dose of study product.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"334","spread":null},{"groupId":"OG001","value":"159","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"171","spread":null},{"groupId":"OG001","value":"110","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"151","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Frequency of Premature Discontinuation of Dosing Due to Adverse Events","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Frequency of Premature Discontinuation of Dosing Due to Chronic/Recurrent Gastrointestinal Adverse Events","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Chronic/Recurrent Gastrointestinal Adverse Events Resolving <2, Between 2-4, Between 4-12, and â‰¥ 12 Weeks Following Discontinuation of Dosing","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Frequency of Allergic Hypersensitivity Adverse Events Normalized for Duration of Treatment","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1434","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1184","spread":null},{"groupId":"OG001","value":"83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"911","spread":null},{"groupId":"OG001","value":"65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"557","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"510","spread":null},{"groupId":"OG001","value":"106","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"374","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"361","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"305","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"296","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"266","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"251","spread":null},{"groupId":"OG001","value":"117","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"195","spread":null},{"groupId":"OG001","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"170","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"164","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"159","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"139","spread":null},{"groupId":"OG001","value":"62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"127","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Frequency of Anaphylaxis as Defined in the Protocol","description":"Anaphylaxis is likely when any 1 of the 3 following sets of criteria is fulfilled:\n\n1. Acute onset of an illness (minutes to hours) with involvement of: (a) Skin/mucosal tissue (eg, generalized hives, itch/flush, swollen lips/tongue/uvula); AND (b) Airway compromise (eg, dyspnea, stridor, wheeze/bronchospasm, hypoxia, reduced PEFR); AND/OR (c) Reduced BP or associated symptoms (eg, hypotonia, syncope, incontinence).\n2. Two or more of the following that occur rapidly after exposure to the allergen (minutes to hours): (a) Skin/mucosal tissue; (b) Airway compromise; (c) Reduced BP or associated symptoms; (d) Persistent GI symptoms (eg, nausea, vomiting, crampy abdominal pain).\n3. Reduced BP after exposure to the allergen (minutes to hours). Infants and children: low systolic BP (age-specific) or \\> 30% drop in systolic BP; Adults: systolic BP \\< 90 mm Hg or \\> 30% drop from their baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Frequency of Epinephrine Use as Rescue Medication","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Frequency of Accidental Ingestion of Peanut and Other Allergenic Foods","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]}]},{"type":"SECONDARY","title":"Change of Asthma Control Using the Asthma Control Test (ACT) Questionnaire Total Score From Baseline to Interim (80 mg), End of Up-Dosing (300 mg) and Study Exit, Ages 4-11","description":"The Asthma Control Test (ACT) Questionnaire ACT for subjects aged 4-11 years included 4 questions for the subject and 3 questions for the parent; the total score (sum of 7 questions) ranged from 0 (worst control) to 27 (total control)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.9","spread":"2.57"},{"groupId":"OG001","value":"23.7","spread":"2.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.2","spread":"2.52"},{"groupId":"OG001","value":"23.7","spread":"3.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.2","spread":"2.63"},{"groupId":"OG001","value":"23.8","spread":"3.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.0","spread":"3.03"},{"groupId":"OG001","value":"24.5","spread":"3.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"2.54"},{"groupId":"OG001","value":"0.2","spread":"2.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"3.08"},{"groupId":"OG001","value":"0.4","spread":"2.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"3.29"},{"groupId":"OG001","value":"0.7","spread":"2.76"}]}]}]},{"type":"SECONDARY","title":"Change of Asthma Control Using the Asthma Control Test (ACT) Questionnaire Total Score From Baseline to Interim (80 mg), End of Up-Dosing (300 mg) and Study Exit, Ages 12-17","description":"The Asthma Control Test (ACT) Questionnaire ACT for subjects aged 12-17 years consisted of 5 questions, and the total score (sum of 5 questions) ranged from 5 (worst control) to 25 (total control).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.8","spread":"2.40"},{"groupId":"OG001","value":"22.9","spread":"3.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.0","spread":"2.69"},{"groupId":"OG001","value":"23.1","spread":"2.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.7","spread":"1.73"},{"groupId":"OG001","value":"23.2","spread":"2.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.8","spread":"1.74"},{"groupId":"OG001","value":"22.6","spread":"2.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"2.72"},{"groupId":"OG001","value":"0.2","spread":"2.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"1.92"},{"groupId":"OG001","value":"0.5","spread":"3.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"1.68"},{"groupId":"OG001","value":"-0.2","spread":"2.71"}]}]}]},{"type":"SECONDARY","title":"Frequency of Adverse Events That Led to Early Withdrawal","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":337},"commonTop":["Abdominal pain","Throat irritation","Pruritus","Abdominal discomfort","Vomiting"]}}}